Research Study
View Full Study →
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Citation
Brines M., Dunne A., van Velzen M., Proto P., Ostenson C. et al. (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.. Mol Med. DOI: 10.2119/molmed.2014.00215
Abstract
Abstract not available. See citation for source.
Disclaimer: This research summary is for educational purposes only. Always consult with a healthcare professional before making decisions based on scientific research.